BioTuesdays

Category - Markets

Markets

Maxim starts Quoin Pharma at buy; PT $5

Maxim Group initiated coverage of Quoin Pharmaceuticals (NASDAQ:QNRX) with a “buy” rating and price target of $5. The stock closed at $1.74 on Jan.6. Quoin is a clinical-stage company developing therapies for rare...

January 7, 2022
Nkarta Therapeutics
Markets

WB starts Nkarta at OP; fair-value estimate $35

William Blair launched coverage of Nkarta (NASDAQ:NKTX) with an “outperform” rating and fair-value estimate of $35. The stock closed at $14.27 on Jan. 5. Nkarta is developing allogeneic chimeric antigen receptor (CAR)...

January 6, 2022
Cardiff Oncology
Markets

WB starts Cardiff Oncology at outperform

William Blair initiated coverage of Cardiff Oncology (NASDAQ:CRDF) with an “outperform” rating. The stock closed at $6.43 on Jan.4. Cardiff is advancing on vansertib, a specific PLK1 inhibitor, which “we view as a...

January 5, 2022
P3 Health Partners
Markets

WB starts P3 Health Partners at outperform

William Blair launched coverage of P3 Health Partners (NASDAQ:PIII) with an “outperform” rating, projecting 2022 revenue of 815.1-million; 2023 revenue of $1.2-billion; and 2024 revenue of $1.7-billion on adjusted...

January 4, 2022
Pear Therapeutics
Markets

BTIG starts Pear Therapeutics at buy; PT $12

BTIG initiated coverage of Pear Therapeutics (NASDAQ:PEAR) with a “buy” rating and $12 price target. The stock closed at $6.20 on Dec. 31.  Pear is a leader in prescription digital therapeutics (PDTs), with three...

January 3, 2022
Vincerx Logo
Markets

Cantor starts Vincerx Pharma at OW; PT $25

Cantor Fitzgerald initiated coverage of Vincerx Pharma (NASDAQ:VINC) with an “overweight” rating and $25 price target. The stock closed at $10.30 on Dec. 22. Vincerx is a clinical-stage oncology company that is on track...

December 23, 2021
BioCardia
Markets

HCW starts BioCardia at buy; PT $9

H.C Wainwright initiated coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and price target of $9. The stock closed at $1.71 on Dec. 17. BioCardia is a clinical-stage company focused on the development of cell...

December 20, 2021
ayala logo
Markets

Maxim starts Ayala at buy; PT $22

Maxim Group initiated coverage of Ayala Pharmaceuticals (NASDAQ:AYLA) with a “buy” rating and $22 price target. The stock closed at $9 on Dec. 17. Ayala is developing two gamma-secretase inhibitors – AL101 and...

December 20, 2021
89bio
Markets

HCW starts 89bio at buy; PT $46

H.C. Wainwright launched coverage of 89bio (NADAQ:ETNB) with a “buy” rating and price target of $46. The stock closed at $11.48 on Dec. 17. 89bio is a clinical-stage biopharmaceutical company focused on the development...

December 20, 2021
Vor Logo
Markets

HCW starts Vor Biopharma at buy; PT $26

H.C. Wainwright initiated coverage of Vor Biopharma (NASDAQ:VOR) with a “buy” rating and $26 price target. The stock closed at $12.13 on Dec. 16. Vor is a clinical-stage cell therapy company focused on developing...

December 17, 2021

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.